查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1701378

感染疾病药物市场规模、份额、趋势分析报告：按感染疾病、药物类别、分销管道、地区、细分市场预测，2025-2030 年

Infectious Disease Therapeutics Market Size, Share & Trends Analysis Report By Infection (Bacterial, Viral), By Drug Class (Antibacterial, Antiviral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

感染疾病治疗市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球感染疾病治疗市场预计到2030年将达到2,839.1亿美元，2025年至2030年的复合年增长率为3.5%。

市场成长的主要动力来自于全球人类免疫力缺乏病毒 (HIV)、人类乳突病毒 (HPV)、结核病和肝炎病例的不断增加。

政府机构和私人公司正在大力投资医疗保健领域，用于预防、诊断和治疗感染疾病。预计在预测期内，对治疗感染疾病的新药开发的投资增加以及提高人们对这些疾病的意识提升的倡议的增加将推动市场的发展。此外，随着专利到期以及学名药进入市场，预计感染疾病药物的需求将因价格较低而增加。

此外，这些感染疾病的诊断和治疗可以获得报销，加上製造商在这些疾病高发生率地区免费分发药品，预计将进一步推动市场成长。然而，感染疾病物的低采用率和假药数量预计将在预测期内成长抑制因素。

2016年，北美市场占最大份额。大量製造商的存在、有利的报销情况以及不断增加的医疗保健成本是该地区占最大份额的关键因素。然而，亚太地区很可能在 2017 年至 2025 年期间呈现最高成长率。感染疾病高发病率、亚洲国家经济状况改善、政府越来越多地采取感染疾病治疗措施以及资金筹措活动的活性化是该地区在预测期内实现最高增长率的一些因素。

感染疾病药物市场报告重点

  • 2024年，病毒感染疾病将占据市场主导地位，份额为42.58%。寄生虫感染疾病领域是成长最快的市场，其驱动力包括盛行率的上升、抗药性的增强以及针对疟疾、利什曼原虫症和血吸虫病的全球卫生倡议。
  • 到 2024 年，疫苗将占据抗感染药感染疾病市场的主导地位，占有 32.75% 的份额。这是由于疾病盛行率上升、人们意识增强以及政府强有力的疫苗接种计划所致。由于疟疾、利什曼原虫症和其他寄生虫感染疾病的盛行率不断上升，抗寄生虫药物行业正在经历强劲增长。
  • 受全球住院人数不断增加的推动，预计到 2024 年，医院药局将占据市场主导地位，收入份额将达到 52.19%。由于网路药局的日益普及，其他药局领域正在经历快速增长，这增加了感染疾病药物的可及性和便利性。
  • 2024年感染疾病治疗药物市场中，北美占据主导地位，全球份额为38.09%。由于细菌和病毒感染疾病的日益流行以及医疗保健基础设施的改善，亚太地区的感染疾病治疗市场正在扩大。

目录

第一章调查方法与范围

第二章执行摘要

第三章感染疾病药物市场变数、趋势与范围

  • 市场展望
  • 市场动态
    • 市场成长要素分析
    • 市场限制因素分析
  • 感染疾病物抗药性的出现及其相关副作用
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析

第四章感染疾病药物市场：感染疾病业务分析

  • 2024年及2030年感染疾病市场占有率
  • 感染疾病细分仪表板
  • 市场规模、预测与趋势分析（依感染疾病，2018-2030 年）
  • 细菌感染疾病
  • 病毒感染
  • 霉菌感染疾病
  • 寄生虫感染疾病

第五章感染疾病药物市场：依药物类别的业务分析

  • 2024 年及 2030 年药品类别市场占有率
  • 药品类别细分仪表板
  • 2018-2030 年药品类别市场规模、预测及趋势分析
  • 抗菌剂
  • 抗病毒药物
  • 抗真菌药物
  • 抗寄生虫药物
  • 疫苗
  • 其他的

第六章感染疾病药物市场：通路业务分析

  • 2024年及2030年分销通路市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院药房
  • 零售药局
  • 其他的

第七章感染疾病药物市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018年至2030年市场规模与预测趋势分析：
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章竞争格局

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Pfizer Inc.
    • AbbVie.
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb
    • Merck &Co., Inc.
    • Sandoz International GmbH
    • B. Braun SE
    • Xellia Pharmaceuticals
    • Mankind Pharma
    • Bayer AG
    • AstraZeneca
    • Boehringer Ingelheim International GmbH.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
Product Code: GVR-1-68038-580-9

Infectious Disease Therapeutics Market Growth & Trends:

The global infectious disease therapeutics market size is expected to reach USD 283.91 billion by 2030, registering a CAGR of 3.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing number of Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), TB, and hepatitis cases globally.

Government and private organizations are investing heavily in the healthcare sector to prevent, diagnose, and treat infectious diseases; rising investments for development of new drugs to treat infectious diseases, and increasing number of initiatives for creating awareness about these conditions are expected to boost the market during the forecast period. Furthermore, increasing number of patent expirations and entry of generic drugs in the market are expected to increase the demand for infectious disease therapeutics due to their low prices.

In addition, availability of reimbursement for diagnosis & treatment of these infections and free distribution of drugs by manufacturers in regions with high incidence of these diseases are factors further expected to propel the market growth. However, low penetration rate of anti-infective and availability of large number of counterfeit drugs are expected to restraint the market growth during the forecast period.

North American market held the largest share in 2016. Presence of large number of manufacturers, favorable reimbursement scenario, and increasing healthcare expenditure are major factors responsible for the largest share held by this region. However, Asia Pacific is likely to grow at the highest rate between 2017 and 2025. High prevalence of infectious diseases; improving economic conditions in Asian countries, rising government initiatives to increase the adoption of treatments for infectious diseases, and rising funding activities are factors that can be attributed for the highest growth rate of this region during the forecast period.

Infectious Disease Therapeutics Market Report Highlights:

  • Viral infections dominated the market with a 42.58% share in 2024. The parasitic infections segment is the fastest-growing market, driven by increasing prevalence, rising drug resistance, and global health initiatives targeting malaria, leishmaniasis, and schistosomiasis.
  • Vaccines dominated the anti-infective agents market with a 32.75% share in 2024, driven by rising disease prevalence, growing awareness, and strong government immunization programs. The antiparasitic drugs segment is experiencing significant growth due to the rising prevalence of malaria, leishmaniasis, and other parasitic infections.
  • Hospital pharmacies dominated the market with a revenue share of 52.19% in 2024, driven by the rising number of hospitalizations globally.The other pharmacy segment is experiencing rapid growth due to the increasing adoption of online pharmacies, which enhance accessibility and convenience for infectious disease therapeutics.
  • North America holds a leading position in the 2024 infectious disease therapeutics market, accounting for 38.09% of the global share. The infectious disease therapeutics market in Asia Pacific is expanding due to the rising prevalence of bacterial and viral infections and improving healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Infection
    • 1.2.2. Drug Class
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Infectious Disease Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing incidence of infectious diseases
      • 3.2.1.2. Increasing incidence of infectious diseases
      • 3.2.1.3. Rising initiatives for the awareness of infectious diseases
    • 3.2.2. Market Restraint Analysis
  • 3.3. 3.3.1 Emergence of resistance to infectious disease therapeutic drugs and adverse effects associated with them
  • 3.4. Business Environment Analysis
    • 3.4.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.4.1.1. Supplier Power
      • 3.4.1.2. Buyer Power
      • 3.4.1.3. Substitution Threat
      • 3.4.1.4. Threat of New Entrants
      • 3.4.1.5. Competitive Rivalry
    • 3.4.2. PESTLE Analysis
    • 3.4.3. Pipeline Analysis

Chapter 4. Infectious Disease Therapeutics Market: Infections Business Analysis

  • 4.1. Infections Market Share, 2024 & 2030
  • 4.2. Infections Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Infections, 2018 to 2030 (USD Million)
  • 4.4. Bacterial Infections
    • 4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Viral Infections
    • 4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2. Human Immunodeficiency Virus (HIV/AIDS)
      • 4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.3. Hepatitis (Hepatitis B, Hepatitis C)
      • 4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.4. Influenza
      • 4.5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.5. Others
      • 4.5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6. Fungal Infections
    • 4.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.7. Parasitic Infections
    • 4.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Infectious Disease Therapeutics Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 5.4. Antibacterials
    • 5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. Antivirals
    • 5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Antifungals
    • 5.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. Antiparasitic Drugs
    • 5.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.8. Vaccines
    • 5.8.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Infectious Disease Therapeutics Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospitals Pharmacies
    • 6.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Infectious Disease Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Infectious Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Infectious Disease Therapeutics Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Pfizer Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Infection Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. AbbVie.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Infection Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Gilead Sciences, Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Infection Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Bristol-Myers Squibb
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Infection Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Merck & Co., Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Infection Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Sandoz International GmbH
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Infection Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. B. Braun SE
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Infection Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Xellia Pharmaceuticals
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Infection Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Mankind Pharma
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Infection Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Bayer AG
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Infection Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. AstraZeneca
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Infection Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. Boehringer Ingelheim International GmbH.
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Infection Benchmarking
      • 8.5.12.4. Strategic Initiatives
    • 8.5.13. Novartis AG
      • 8.5.13.1. Overview
      • 8.5.13.2. Financial Performance
      • 8.5.13.3. Infection Benchmarking
      • 8.5.13.4. Strategic Initiatives
    • 8.5.14. F. Hoffmann-La Roche Ltd
      • 8.5.14.1. Overview
      • 8.5.14.2. Financial Performance
      • 8.5.14.3. Infection Benchmarking
      • 8.5.14.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 List of Parameters
  • Table 4 List of Distributors
  • Table 5 Global Infectious Disease Therapeutics Market, By Region, 2018 - 2030 (USD Million)
  • Table 6 Global Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 7 Global Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 8 Global Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 9 North America Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 10 North America Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 11 North America Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 12 North America Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 13 U.S. Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 14 U.S. Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 15 U.S. Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Canada Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 17 Canada Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Canada Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Mexico Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 20 Mexico Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 21 Mexico Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 22 Europe Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 23 Europe Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 24 Europe Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 25 Europe Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 26 Germany Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 27 Germany Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 28 Germany Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 29 UK Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 30 UK Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 31 UK Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 32 France Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 33 France Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 34 France Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 35 Italy Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 36 Italy Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 37 Italy Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 38 Spain Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 39 Spain Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 40 Spain Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Denmark Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 42 Denmark Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 43 Denmark Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Sweden Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 45 Sweden Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 46 Sweden Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Norway Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 48 Norway Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 49 Norway Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Japan Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 55 Japan Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 56 Japan Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 57 China Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 58 China Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 59 China Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 60 India Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 61 India Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 62 India Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 63 South Korea Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 64 South Korea Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 65 South Korea Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 66 Australia Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 67 Australia Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 68 Australia Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Thailand Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 70 Thailand Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 71 Thailand Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Latin America Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 73 Latin America Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 74 Latin America Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 75 Latin America Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 76 Brazil Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 77 Brazil Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 78 Brazil Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 79 Argentina Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 80 Argentina Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 81 Argentina Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 85 Middle East & Africa Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 89 South Africa Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 90 South Africa Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 91 South Africa Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 92 UAE Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 93 UAE Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 94 UAE Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 97 Kuwait Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Astaxanthin market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Source and product segment snapshot
  • Fig. 10 Application segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market value, 2024 (USD Billion)
  • Fig. 13 Market trends & outlook
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTEL analysis
  • Fig. 16 Infectious Disease Therapeutics Market Outlook Key Takeaways
  • Fig. 17 Infectious Disease Therapeutics Market: Infection Movement Analysis
  • Fig. 18 Global Infectious Disease Therapeutics Market, by Infection, 2018 - 2030 (USD Million)
  • Fig. 19 Bacterial Infections Market, 2018 - 2030 (USD Million)
  • Fig. 20 Viral Infections Market, 2018 - 2030 (USD Million)
  • Fig. 21 Human Immunodeficiency Virus (HIV/AIDS) Market, 2018 - 2030 (USD Million)
  • Fig. 22 Hepatitis (Hepatitis B, Hepatitis C) Market, 2018 - 2030 (USD Million)
  • Fig. 23 Influenza Market, 2018 - 2030 (USD Million)
  • Fig. 24 Other Viral Infections Market, 2018 - 2030 (USD Million)
  • Fig. 25 Fungal Infections Market, 2018 - 2030 (USD Million)
  • Fig. 26 Parasitic Infections Market, 2018 - 2030 (USD Million)
  • Fig. 27 Global Infectious Disease Therapeutics Market: Drug Class Movement Analysis
  • Fig. 28 Global Infectious Disease Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Fig. 29 Antibacterials Market, 2018 - 2030 (USD Million)
  • Fig. 30 Antivirals Market, 2018 - 2030 (USD Million)
  • Fig. 31 Antifungals Market, 2018 - 2030 (USD Million)
  • Fig. 32 Antiparasitic Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 33 Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 34 Others Market, 2018 - 2030 (USD Million)
  • Fig. 35 Global Infectious Disease Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Fig. 36 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 37 Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 38 Others Market, 2018 - 2030 (USD Million)
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Canada infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Mexico infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Europe infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Germany infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 France infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Italy infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Spain infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Denmark infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Sweden infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Norway infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Asia Pacific infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Japan infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 China infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 India infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Australia infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Latin America infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Brazil infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Argentina infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 MEA infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 South Africa infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Saudi Arabia infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 UAE infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Kuwait infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 List of key emerging company's/disruptors/innovators